Lab21 to Provide Cancer Test for Patients Taking Amgen Drug | GenomeWeb
NEW YORK (GenomeWeb News) – Amgen said today that it has partnered with Lab21 to launch a new genetic test for patients in the UK taking Amgen’s Vectibix (panitumumab) for advanced bowel cancer.
 
The screening test was developed by British molecular diagnostics firm DxS, which sells a range of cancer mutation diagnostic products.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.